Join BIOCYTOGEN at 2nd Annual Legorreta Cancer Center Translational Research Symposium
We are thrilled to announce our participation in the 2nd Annual Legorreta Cancer Center Translational Research Symposium 2024 at Brown University on September 14th! This year’s theme, “The Ins and Outs of Cancer,” will feature presentations by seven leading cancer researchers. This prestigious event attracts clinical scientists from around the world, all passionate about advancing cancer research. Join us to delve into the latest advancements in lab-based, clinical, and translational research.
What is the Annual Legorreta Cancer Center Translational Research Symposium?
The Legorreta Cancer Center Translational Research Symposium is a premier gathering of scientific excellence, international collaboration, and unparalleled networking opportunities. This annual event focuses on advancing the fight against cancer by bringing together the foremost experts in the field. Attendees will experience a showcase of groundbreaking research, including the latest in lab-based, clinical, and translational studies.
With the theme “The Ins and Outs of Cancer,” this symposium will feature presentations from seven leading cancer researchers who are pushing the boundaries of our understanding and treatment of cancer. The event serves as a critical platform for discussing innovative approaches, addressing key challenges in the oncology field, and exploring new frontiers in cancer research.
Event Overview
Venue: Warren Alpert Medical School of Brown University | Lecture Hall 160, 222 Richmond St, Providence, RI 02912
Date: September 14th, 2024
Event Schedule
This is a one day symposium to be held in the Warren Alpert Medical School. Breakfast and lunch will be provided, plus a cocktail reception to follow the programming. It will be a full day of insights and innovation in cancer research with thorough discussion. For a more comprehensive look at the schedule, including session times and detailed information on each presentation, please refer to the registration website.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the 2nd Annual Legorreta Cancer Center Translational Research Symposium in Brown University!
